NYSE$GMED

Globus Medical Inc · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Globus Medical's Q1 2020 financial results were announced, revealing a sales increase and resilience amidst the COVID-19 pandemic.

Globus Medical reported a 4.2% increase in worldwide sales, reaching $190.6 million in Q1 2020. Despite the COVID-19 pandemic's estimated $20 million negative impact on sales, the company maintained profitability with a net income of $25.9 million and a non-GAAP adjusted EBITDA of 26.5% of sales. The company launched three new spine products during the quarter and ended the quarter with $657 million in cash, cash equivalents and marketable securities.

  • Worldwide sales increased by 4.2% to $190.6 million.
  • Net income for the first quarter was $25.9 million.
  • Diluted EPS was $0.25, and non-GAAP diluted EPS was $0.29.
  • Non-GAAP adjusted EBITDA was 26.5% of sales.

Headline financials

Total Revenue

$191M

Previous: $183M+4.2%
EPS (adj)

$0.29

Previous: $0.36-19.4%
Adjusted EBITDA

$26.50

Previous: $31.10-14.8%
Capital Expenditures

$22.3M

Previous: -$28.2M+179.3%
Free Cash Flow

$20M

Previous: $5.06M+295.2%
Net Income

$25.9M

Previous: $33.2M-21.9%
Operating Income

$28.4M

Previous: $37.1M-23.3%
Gross Profit

$142M

Previous: $141M+0.4%
Cash & Equivalents

$167M

Previous: $130M+28.3%
Total Assets

$1.48B

Previous: $1.34B+10.7%
Stock-Based Comp

$6.81M

Previous: $6.45M+5.6%

Revenue & EPS history

Globus Medical · Revenue · Quarterly

$191M

Q1 2020+4.2%vs Q1 2019
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Globus Medical · $191M total across 2 segments · Q1 2020

  • Musculoskeletal Solutions
    $183M+3.9%
  • Enabling Technologies
    $8.04M+11.8%

Forward guidance

Globus Medical withdrew its full year 2020 guidance due to the uncertainties related to the COVID-19 pandemic.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

+0.8%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+0.9%

Avg return

30 days after

57%

34 / 60 earnings

Positive

+36.0%

Q3 2025

Best reaction

-23.0%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.1%-14.6%-10.4%
Q4 2025+4.6%+2.1%-8.8%
Q3 2025+36.0%+37.3%+47.6%
Q1 2025-23.0%-19.7%-17.3%
Q4 2024-4.6%-4.9%-12.5%
Q3 2024+10.7%+8.2%+11.2%
Q2 2024+4.0%+8.0%+4.4%
Q1 2024+22.8%+28.7%+31.6%
Q4 2023+2.2%+4.6%-3.1%
Q3 2023-1.4%-5.1%-2.5%
Q2 2023-5.0%-4.8%-9.1%
Q1 2023+2.9%-0.3%-1.8%
Q4 2022-1.2%-21.9%-29.2%
Q3 2022-4.2%+9.4%+11.5%
Q2 2022+5.4%+6.9%-2.4%
Q1 2022+0.1%+5.2%+0.1%
Q4 2021-3.1%-3.7%+1.3%
Q3 2021+0.2%-4.3%-19.4%
Q2 2021-3.3%-3.0%+1.3%
Q1 2021+3.1%+3.0%-0.9%
Q4 2020-5.7%-5.2%-10.2%
Q3 2020+2.4%+3.5%+16.9%
Q2 2020+18.5%+13.4%+13.3%
Q1 2020+8.1%+0.6%+21.4%
Q4 2019-2.1%-9.7%-29.0%
Q3 2019+3.6%+4.2%+8.2%
Q2 2019+9.9%+6.1%+12.0%
Q1 2019-1.9%-2.0%-11.0%
Q4 2018+0.2%-2.2%-0.3%
Q3 2018-8.7%-9.9%-19.4%
Q2 2018+4.7%+1.7%+3.5%
Q1 2018-3.4%+0.7%+12.6%
Q4 2017+0.5%-1.8%+2.2%
Q3 2017+9.8%+19.7%+24.3%
Q2 2017-5.2%-3.7%-1.7%
Q1 2017+4.9%+1.0%+4.7%
Q4 2016-3.1%-2.1%+2.5%
Q3 2016-5.6%-4.9%+7.1%
Q2 2016-14.3%-11.7%-13.1%
Q1 2016-9.4%
Q4 2015+4.2%
Q3 2015+12.3%
Q2 2015+2.5%
Q1 2015+4.8%
Q4 2014-0.9%
Q3 2014+7.0%
Q2 2014-16.8%
Q1 2014+6.1%
Q4 2013+1.4%
Q3 2013+7.1%
Q2 2013+2.3%
Q1 2013+7.9%
Q1 2011+0.4%
Q4 2010+0.4%
Q4 2012+5.8%
Q3 2011-20.7%
Q3 2012-16.2%
Q4 2011-0.7%
Q2 2011-0.7%
Q2 2012+0.0%
Q1 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro